CA2456976A1 - Expandable gastric retention device - Google Patents

Expandable gastric retention device Download PDF

Info

Publication number
CA2456976A1
CA2456976A1 CA002456976A CA2456976A CA2456976A1 CA 2456976 A1 CA2456976 A1 CA 2456976A1 CA 002456976 A CA002456976 A CA 002456976A CA 2456976 A CA2456976 A CA 2456976A CA 2456976 A1 CA2456976 A1 CA 2456976A1
Authority
CA
Canada
Prior art keywords
agents
retention device
gastric retention
gastric
gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002456976A
Other languages
English (en)
French (fr)
Inventor
James W. Ayres
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon State Board of Higher Education
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2456976A1 publication Critical patent/CA2456976A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0419—Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002456976A 2001-08-16 2001-10-22 Expandable gastric retention device Abandoned CA2456976A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31307801P 2001-08-16 2001-08-16
US60/313,078 2001-08-16
PCT/US2001/046146 WO2003015745A1 (en) 2001-08-16 2001-10-22 Expandable gastric retention device

Publications (1)

Publication Number Publication Date
CA2456976A1 true CA2456976A1 (en) 2003-02-27

Family

ID=23214285

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002456976A Abandoned CA2456976A1 (en) 2001-08-16 2001-10-22 Expandable gastric retention device

Country Status (14)

Country Link
EP (1) EP1416914A1 (pt)
JP (1) JP2005501097A (pt)
KR (1) KR20040032918A (pt)
CN (1) CN1543337A (pt)
BR (1) BR0117123A (pt)
CA (1) CA2456976A1 (pt)
CO (1) CO5670360A2 (pt)
IL (1) IL160363A0 (pt)
MX (1) MXPA04001388A (pt)
NO (1) NO20040611L (pt)
NZ (1) NZ531461A (pt)
PL (1) PL368327A1 (pt)
WO (1) WO2003015745A1 (pt)
ZA (1) ZA200402066B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2466808C (en) 2001-11-21 2009-01-27 E-Z-Em, Inc. Formulations for use in medical or diagnostic procedures
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
US7785291B2 (en) 2005-03-01 2010-08-31 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
US7699863B2 (en) 2005-03-01 2010-04-20 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
KR20090053783A (ko) * 2006-07-19 2009-05-27 스미스클라인 비참 코포레이션 감마 섬광조영술 평가를 위한 제형의 방사선표지 방법
CN102552103B (zh) * 2010-12-20 2013-11-20 西安力邦医药科技有限责任公司 拉米夫定固体分散体、其制备方法、药物组合物和用途
WO2013183058A2 (en) 2012-06-07 2013-12-12 Tulip Medical Ltd. Expanded device
EP3091962B1 (en) 2013-12-05 2022-06-08 Epitomee Medical Ltd. Retentive devices and systems for in-situ release of pharmaceutical active agents
BR112016028957B1 (pt) 2014-06-11 2021-12-14 The Brigham And Women's Hospital, Inc. Estrutura de residência gástrica
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
CA2983272C (en) 2015-05-01 2023-08-29 Massachusetts Institute Of Technology Triggerable shape memory induction devices
WO2017070612A1 (en) 2015-10-23 2017-04-27 Lyndra, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
CN108697649A (zh) 2015-12-08 2018-10-23 林德拉有限公司 用于胃驻留系统的几何构型
CN110022861A (zh) 2016-09-30 2019-07-16 林德拉有限公司 用于金刚烷类药物缓释的胃驻留系统
US11337919B2 (en) * 2017-12-18 2022-05-24 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
TR201914116A2 (tr) * 2019-09-17 2021-04-21 Univ Yeditepe Doğal bi̇yomateryaller i̇le kri̇yojelleri̇n üreti̇m yöntemi̇ ve bu kri̇yojelleri̇n yumuşak doku i̇skelesi̇ veya i̇laç taşiyici si̇stem olarak kullanimi
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764380A (en) * 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
AU8699298A (en) * 1997-08-11 1999-03-01 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
EP1281397A1 (en) * 1998-09-14 2003-02-05 Ranbaxy Laboratories Limited Orally administered controlled drug delivery system providing temporal and spatial control
JP2000256216A (ja) * 1999-03-04 2000-09-19 Meiji Milk Prod Co Ltd ゲル組成物
KR20030013460A (ko) * 2000-06-23 2003-02-14 테바 파마슈티컬 인더스트리즈 리미티드 치료제의 위 체류 및 방출 조절을 위한 급속 팽창성조성물과 이 조성물을 포함하는 제형

Also Published As

Publication number Publication date
JP2005501097A (ja) 2005-01-13
ZA200402066B (en) 2005-05-09
PL368327A1 (en) 2005-03-21
KR20040032918A (ko) 2004-04-17
MXPA04001388A (es) 2004-05-27
BR0117123A (pt) 2004-09-28
WO2003015745A1 (en) 2003-02-27
NO20040611L (no) 2004-04-16
NZ531461A (en) 2008-03-28
IL160363A0 (en) 2004-07-25
CO5670360A2 (es) 2006-08-31
EP1416914A1 (en) 2004-05-12
CN1543337A (zh) 2004-11-03

Similar Documents

Publication Publication Date Title
US20040219186A1 (en) Expandable gastric retention device
JP3382950B2 (ja) 医薬品用の徐放性マトリックス
Shaha et al. An overview of a gastro-retentive floating drug delivery system
Reddy et al. Floating dosage systems in drug delivery
KR100618234B1 (ko) 다공성 입자를 포함하는 제형
EP1750717B1 (en) Controlled release pharmaceutical compositions with improved bioavailability
CA2456976A1 (en) Expandable gastric retention device
AU2009313867A1 (en) Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low pH and methods of use thereof
WO2003035177A2 (en) Optimal polymer mixtures for gastric retentive tablets
AU2002337974A1 (en) Optimal polymer mixtures for gastric retentive tablets
Vasave A REVIEW ON: FLOATING DRUG DELIVERY SYSTEM
WO2022200971A1 (en) A method for the production of gastroretentive compact matrices for the controlled release of active substances and compact matrices thus obtained
JP3122478B2 (ja) 下部消化管放出型経口製剤
JP4224866B2 (ja) 溶解時間を制御した基剤
AU2002225872A1 (en) Expandable gastric retention device
JP2018500278A (ja) 外部粘膜に適用する剤形物品
Katakam et al. Floating drug delivery systems: a review
AU2014368504B2 (en) Gastro-retentive oral pharmaceutical compositions
Singh et al. Gastroretentive Delivery
JPWO2019039420A1 (ja) 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
Yuganya Design and Evaluation of Gastro Retentive Floating Drug Delivery System of Valsartan.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued